Workflow
心血管医疗器械
icon
Search documents
打造“京西福地” 门头沟交出“两区”建设五年答卷
Xin Jing Bao· 2025-09-24 11:54
门头沟区相关负责人介绍,五年来,门头沟区坚持以制度创新为核心引擎,一批首创性、引领性政策落 地生花。"社会投资低风险工程建设项目审批改革新政"等多项创新实践入选市级案例库,探索知识产权 质押融资助力企业盘活无形资产的模式成为全市营商环境改革创新范例。随着《北京数据基础制度先行 区门头沟片区方案》的发布,区域在数据要素市场化配置改革中率先破题,着力打造政策与价值高地。 同时,通过构建完善的知识产权创造、运用、保护、管理、服务全链条体系,为创新发展筑牢法治屏 障。 门头沟区聚焦人工智能、超高清数字视听、心血管医疗器械三大细分赛道,奋力打造特色鲜明的产业集 聚区。其中,"京西智谷"品牌影响力日益凸显,不仅入选全市首批未来产业育新基地,更建成了全市最 大的600P国产自主创新算力集群,并吸引了首批大模型生态服务站、全国首个实体化算法登记服务中 心等关键平台落户。在超高清数字视听领域,挂牌全市唯一的计算视听创新应用示范区,携手央视网共 建AGI联合研究中心,成功训练发布自有知识产权文生视频大模型"潭柘智空",并孵化出多个业界瞩目 的创新应用。以"中国心谷"为目标的心血管医疗器械产业也取得重要突破,通过优化"1+1+1" ...
半年盘点|美国医疗企业财报密集公布,哪些业务最赚钱?
Di Yi Cai Jing· 2025-07-24 10:15
Core Insights - The demand for medical devices used in innovative drug development remains strong, with cardiovascular medical devices and surgical robots being key growth drivers, while the diagnostic testing market continues to show weakness [1] Group 1: Company Performance - Thermo Fisher Scientific raised its annual profit forecast, citing strong demand for drug development products, leading to a 12% increase in its stock price [3] - Danaher also raised its annual profit forecast, highlighting a stable demand from pharmaceutical clients for bioprocessing services, with monoclonal antibodies accounting for over 75% of its bioprocessing revenue [3] - Boston Scientific increased its annual profit forecast due to strong demand for cardiovascular medical devices and reduced its tariff-related cost impact from $200 million to $100 million [4] - Johnson & Johnson reported over 6% growth in medical device sales, reaching $8.54 billion, driven by strong performance in cardiovascular devices [4][5] - Intuitive Surgical reported better-than-expected profits and revenues, with a 17% year-over-year increase in global da Vinci surgical procedures [5] Group 2: Market Trends - The cardiovascular medical device market is experiencing robust growth, with companies like Boston Scientific and Johnson & Johnson leading the way [4][5] - The surgical robotics sector is becoming a critical growth engine for medical technology companies, benefiting from increased accessibility in minimally invasive therapies [5] - The diagnostic business is facing challenges, as evidenced by Abbott's downward revision of profit expectations due to declining demand [5]